ATE250602T1 - Pyrimido(6,1-a)isochinolinonderivate - Google Patents

Pyrimido(6,1-a)isochinolinonderivate

Info

Publication number
ATE250602T1
ATE250602T1 AT00920857T AT00920857T ATE250602T1 AT E250602 T1 ATE250602 T1 AT E250602T1 AT 00920857 T AT00920857 T AT 00920857T AT 00920857 T AT00920857 T AT 00920857T AT E250602 T1 ATE250602 T1 AT E250602T1
Authority
AT
Austria
Prior art keywords
pyrimido
derivatives
isochinolinone
isoquinolin
relates
Prior art date
Application number
AT00920857T
Other languages
English (en)
Inventor
Alexander William Oxford
David Jack
Original Assignee
Vernalis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9907454.4A external-priority patent/GB9907454D0/en
Priority claimed from GBGB9909802.2A external-priority patent/GB9909802D0/en
Application filed by Vernalis Ltd filed Critical Vernalis Ltd
Application granted granted Critical
Publication of ATE250602T1 publication Critical patent/ATE250602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT00920857T 1999-03-31 2000-03-29 Pyrimido(6,1-a)isochinolinonderivate ATE250602T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9907454.4A GB9907454D0 (en) 1999-03-31 1999-03-31 Compounds
GBGB9909802.2A GB9909802D0 (en) 1999-04-28 1999-04-28 Compounds
PCT/GB2000/001193 WO2000058308A1 (en) 1999-03-31 2000-03-29 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE

Publications (1)

Publication Number Publication Date
ATE250602T1 true ATE250602T1 (de) 2003-10-15

Family

ID=26315369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920857T ATE250602T1 (de) 1999-03-31 2000-03-29 Pyrimido(6,1-a)isochinolinonderivate

Country Status (16)

Country Link
US (5) US6794391B2 (de)
EP (1) EP1165558B1 (de)
JP (1) JP4685243B2 (de)
CN (1) CN100415743C (de)
AT (1) ATE250602T1 (de)
AU (1) AU773504B2 (de)
BR (1) BRPI0009446B8 (de)
CA (1) CA2368413C (de)
DE (1) DE60005493T2 (de)
DK (1) DK1165558T3 (de)
ES (1) ES2208310T3 (de)
MX (1) MXPA01009846A (de)
NO (1) NO20014728L (de)
NZ (1) NZ514158A (de)
PT (1) PT1165558E (de)
WO (1) WO2000058308A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773504B2 (en) * 1999-03-31 2004-05-27 Verona Pharma Plc Derivatives of pyrimido(6,1-a)isoquinolin-4-one
CA2611907A1 (en) * 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
EP2138495A1 (de) * 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
CN103313985B (zh) * 2010-08-09 2016-03-02 维罗纳制药Plc公司 嘧啶并[6,1-a]异喹啉-4-酮化合物的结晶型
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
DK2968313T3 (en) * 2013-03-15 2018-04-16 Verona Pharma Plc drug combination
PL3142701T3 (pl) * 2014-05-12 2018-11-30 Verona Pharma Plc Nowe leczenie
EP3332767B1 (de) * 2014-09-15 2019-03-20 Verona Pharma PLC Flüssige inhalationsformulierung mit rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
WO2020011254A1 (zh) 2018-07-13 2020-01-16 正大天晴药业集团股份有限公司 作为pde3/pde4双重抑制剂的三并环类化合物
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
AU2021207159A1 (en) * 2020-01-15 2022-08-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of PDE3/PDE4 dual inhibitor and use thereof
EP4092025B9 (de) * 2020-01-15 2024-11-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmazeutische zusammensetzung einer tricyclischen pde3/pde4-doppelinhibitorverbindung
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
US20240217974A1 (en) * 2021-04-29 2024-07-04 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Isoquinolone compound and use thereof
EP4423085A1 (de) 2021-10-29 2024-09-04 Teva Pharmaceuticals International GmbH Feste formen von ensifentrin und verfahren zu ihrer herstellung
WO2023109802A1 (zh) * 2021-12-14 2023-06-22 海思科医药集团股份有限公司 三环稠杂环类pde3/4双重抑制及其用途
WO2023138676A1 (zh) * 2022-01-21 2023-07-27 四川海思科制药有限公司 三环稠杂环类pde3/4双重抑制及其用途
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
KR20250048093A (ko) 2022-08-08 2025-04-07 베로나 파마 피엘씨 최저 폐 기능 향상을 위한 엔시펜트린(rpl-554)
JP2025528141A (ja) 2022-08-08 2025-08-26 ヴェローナ ファーマ ピーエルシー 液体医薬組成物
AU2023362721A1 (en) 2022-10-20 2025-04-17 Verona Pharma Plc Treatment of idiopathic pulmonary fibrosis with ensifentrine
KR20250095708A (ko) * 2022-10-28 2025-06-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 이소퀴놀리논계 화합물의 결정형 및 이의 제조 방법
CN117946099A (zh) * 2022-10-28 2024-04-30 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的可药用盐、晶型及其制备方法
CA3272038A1 (en) * 2022-10-28 2025-06-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS
EP4378942A1 (de) 2022-12-02 2024-06-05 Sandoz AG Kristalline form eines pde3/4 inhibitors
US20260015354A1 (en) * 2022-12-14 2026-01-15 Cipla Limited Solid State Forms of Ensifentrine
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025003643A1 (en) 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物
CN118955496B (zh) * 2023-06-28 2026-01-02 郑州德迈药业有限公司 一种化合物及其应用
US20250073240A1 (en) 2023-09-06 2025-03-06 Verona Pharma Plc New treatment
WO2025093848A1 (en) 2023-11-01 2025-05-08 Verona Pharma Plc Ensifentrine for treating bronchiectasis
CN120136869A (zh) * 2023-12-13 2025-06-13 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
CN120136868A (zh) * 2023-12-13 2025-06-13 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
WO2025124462A1 (zh) * 2023-12-13 2025-06-19 石家庄以岭药业股份有限公司 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用
WO2025168546A1 (en) 2024-02-05 2025-08-14 Verona Pharma Plc Ensifentrine for the treatment of copd
US20250249008A1 (en) 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
WO2025168706A1 (en) 2024-02-07 2025-08-14 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
WO2025176871A1 (en) 2024-02-23 2025-08-28 Inke, S.A. Process for preparing pyrimido[6,1-a]isoquinoline-4-ones
WO2025223528A1 (zh) * 2024-04-27 2025-10-30 苏州君健一方生物医药有限公司 嘧啶并[6,1-a]异喹啉-4-酮衍生物
WO2026003867A1 (en) * 2024-06-24 2026-01-02 Neuland Laboratories Limited An improved process for the preparation of ensifentrine and its purification thereof
WO2026012369A1 (zh) * 2024-07-09 2026-01-15 西藏海思科制药有限公司 一种pde3/4双重抑制剂的晶型物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ185900A (en) * 1976-12-10 1981-04-24 Hoechst Ag Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4307092A (en) * 1979-08-13 1981-12-22 Ayerst Mckenna & Harrison, Inc. 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters
US4254121A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 3-Oxo-5H-pyrimido[2,1-c][1,4 ]benzoxazines
US4254118A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1-Oxo-5H-pyrimido[2,1-c][1,4]benzthiazine-2-carboxylic acid esters
ZW6284A1 (en) * 1983-05-05 1985-10-30 Hoffmann La Roche Novel pyrimidone derivatives
IL89167A (en) * 1988-02-10 1994-02-27 Hoffmann La Roche Substituted pyrroles, their manufacture and pharmaceutical compositions containing them
DE3816995A1 (de) * 1988-05-19 1989-11-23 Hoechst Ag Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10287655A (ja) * 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
AU773504B2 (en) * 1999-03-31 2004-05-27 Verona Pharma Plc Derivatives of pyrimido(6,1-a)isoquinolin-4-one

Also Published As

Publication number Publication date
WO2000058308A1 (en) 2000-10-05
US20030036542A1 (en) 2003-02-20
US20040171828A1 (en) 2004-09-02
CN1348453A (zh) 2002-05-08
US20040176353A1 (en) 2004-09-09
BR0009446A (pt) 2002-01-15
DE60005493T2 (de) 2004-07-01
US20080206163A1 (en) 2008-08-28
EP1165558A1 (de) 2002-01-02
JP2002540207A (ja) 2002-11-26
US6794391B2 (en) 2004-09-21
US7105663B2 (en) 2006-09-12
CA2368413C (en) 2008-07-29
NO20014728L (no) 2001-11-23
PT1165558E (pt) 2004-02-27
AU4127400A (en) 2000-10-16
US8242127B2 (en) 2012-08-14
NZ514158A (en) 2000-03-29
US20120302533A1 (en) 2012-11-29
US7378424B2 (en) 2008-05-27
DK1165558T3 (da) 2004-02-09
DE60005493D1 (de) 2003-10-30
BRPI0009446B8 (pt) 2021-05-25
BRPI0009446B1 (pt) 2016-11-01
NO20014728D0 (no) 2001-09-28
EP1165558B1 (de) 2003-09-24
JP4685243B2 (ja) 2011-05-18
AU773504B2 (en) 2004-05-27
CN100415743C (zh) 2008-09-03
ES2208310T3 (es) 2004-06-16
CA2368413A1 (en) 2000-10-05
MXPA01009846A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
DE60005493D1 (de) Pyrimido[6,1-a]isochinolinonderivate
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
WO2001049688A8 (en) Purine derivatives, process for their preparation and use thereof
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
UY26205A1 (es) Derivados de indoloxoacetil piperazina antiviricos
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
WO2004026867A3 (en) Imidazopyridines as cyclin dependent kinase inhibitors
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
TW200420564A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
HUP0500163A3 (en) Pyrazolo [5,1-b]quinazoline derivatives and pharmaceutical compositions thereof as inhibitors of impdh enzyme
BR0010220A (pt) Compostos de pirimidinona
ATE320436T1 (de) Dimere pyrrolobenzodiazepine
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
MY145332A (en) Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
PT1416935E (pt) Derivados de 4-amino-6-fenil-pirrolo[2,3-d]pirimidina
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
TR199802282T2 (xx) Karbolin t�revleri.
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
ES2052629T3 (es) Pirazolo(3,4-d)piridinas, procedimiento para su preparacion y utilizacion como medicamentos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165558

Country of ref document: EP

REN Ceased due to non-payment of the annual fee